Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
15
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Context Therapeutics Inc market cap is $14.7M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Context Therapeutics Inc 52 week high is $3.62 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Context Therapeutics Inc 52 week low is $0.1526 as of November 22, 2026.
Context Therapeutics Inc stock price today is $0.16.
Context Therapeutics Inc stock price yesterday was $0.1686.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Context Therapeutics Inc's P/E ratio is -0.34.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Context Therapeutics Inc P/B ratio is 0.4741.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Context Therapeutics Inc 50-day moving average is $0.2647.